

Uwe Fuhr

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/999179/publications.pdf>

Version: 2024-02-01

126
papers

5,119
citations

101543

36
h-index

95266

68
g-index

129
all docs

129
docs citations

129
times ranked

6012
citing authors

#	ARTICLE	IF	CITATIONS
1	The fate of naringin in humans: A key to grapefruit juice-drug interactions?. <i>Clinical Pharmacology and Therapeutics</i> , 1995, 58, 365-373.	4.7	226
2	Appropriate Phenotyping Procedures for Drug Metabolizing Enzymes and Transporters in Humans and Their Simultaneous Use in the "Cocktail" Approach. <i>Clinical Pharmacology and Therapeutics</i> , 2007, 81, 270-283.	4.7	220
3	Drug Interactions with Grapefruit Juice. <i>Drug Safety</i> , 1998, 18, 251-272.	3.2	217
4	Relative potency of proton-pump inhibitors" comparison of effects on intragastric pH. <i>European Journal of Clinical Pharmacology</i> , 2009, 65, 19-31.	1.9	204
5	Time response of cytochrome P450 1A2 activity on cessation of heavy smoking*1. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 76, 178-184.	4.7	192
6	Should We Use N -Acetyltransferase Type 2 Genotyping To Personalize Isoniazid Doses?. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 1733-1738.	3.2	187
7	Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and in saliva. <i>Pharmacogenetics and Genomics</i> , 1994, 4, 109-116.	5.7	165
8	Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors. <i>Clinical Pharmacokinetics</i> , 2011, 50, 551-603.	3.5	163
9	An amperometric biosensor with human CYP3A4 as a novel drug screening tool. <i>Biochemical Pharmacology</i> , 2003, 65, 1817-1826.	4.4	160
10	Pharmacogenetics-based therapeutic recommendations " ready for clinical practice?. <i>Nature Reviews Drug Discovery</i> , 2005, 4, 639-647.	46.4	147
11	Toxicokinetics of Acrylamide in Humans after Ingestion of a Defined Dose in a Test Meal to Improve Risk Assessment for Acrylamide Carcinogenicity. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006, 15, 266-271.	2.5	139
12	Induction of Drug Metabolising Enzymes. <i>Clinical Pharmacokinetics</i> , 2000, 38, 493-504.	3.5	124
13	Inhibitory Effects of Silibinin on Cytochrome P-450 Enzymes in Human Liver Microsomes. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2000, 86, 250-256.	0.0	118
14	Evaluation of caffeine as a test drug for CYP1A2, NAT2 and CYP2E1 phenotyping in man by in vivo versus in vitro correlations. <i>Pharmacogenetics and Genomics</i> , 1996, 6, 159-176.	5.7	117
15	Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype. <i>Clinical Pharmacology and Therapeutics</i> , 2006, 80, 657-667.	4.7	106
16	Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors. <i>Clinical Pharmacokinetics</i> , 2011, 50, 371-403.	3.5	95
17	Pharmacogenetics of Oral Anticoagulants. <i>Clinical Pharmacokinetics</i> , 2008, 47, 565-594.	3.5	94
18	Effects of grapefruit juice and smoking on verapamil concentrations in steady state. <i>European Journal of Clinical Pharmacology</i> , 2002, 58, 45-53.	1.9	88

#	ARTICLE	IF	CITATIONS
19	Clinical Pharmacokinetics of Trosipium Chloride. <i>Clinical Pharmacokinetics</i> , 2005, 44, 701-720.	3.5	85
20	Absorption, Pharmacokinetics, and Safety of Triclosan after Dermal Administration. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 570-572.	3.2	83
21	Effects of grapefruit juice on the pharmacokinetics of sildenafil. <i>Clinical Pharmacology and Therapeutics</i> , 2002, 71, 21-29.	4.7	77
22	Effect of Ginkgo biloba special extract EGb 761Â® on human cytochrome P450 activity: a cocktail interaction study in healthy volunteers. <i>European Journal of Clinical Pharmacology</i> , 2012, 68, 553-560.	1.9	76
23	Drug metabolism biosensors: electrochemical reactivities of cytochrome P450cam immobilised in synthetic vesicular systems. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 1998, 17, 1101-1110.	2.8	69
24	Cytochrome P 450 2C9 phenotyping using low-dose tolbutamide. <i>European Journal of Clinical Pharmacology</i> , 2004, 60, 165-171.	1.9	66
25	Pharmacogenomics education in medical and pharmacy schools: conclusions of a global survey. <i>Pharmacogenomics</i> , 2019, 20, 643-657.	1.3	65
26	Impaired hepatic drug and steroid metabolism in congenital adrenal hyperplasia due to P450 oxidoreductase deficiency. <i>European Journal of Endocrinology</i> , 2010, 163, 919-924.	3.7	64
27	CYP2D7â€“2D6 hybrid tandems: identification of novel CYP2D6 duplication arrangements and implications for phenotype prediction. <i>Pharmacogenomics</i> , 2010, 11, 43-53.	1.3	63
28	In vivo Role of Cytochrome P450 2E1 and Glutathione-S-Transferase Activity for Acrylamide Toxicokinetics in Humans. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 433-443.	2.5	61
29	Profiling of mercapturic acids of acrolein and acrylamide in human urine after consumption of potato crisps*. <i>Molecular Nutrition and Food Research</i> , 2012, 56, 1825-1837.	3.3	61
30	Clinical Pharmacokinetics and Pharmacodynamics of Solifenacin. <i>Clinical Pharmacokinetics</i> , 2009, 48, 281-302.	3.5	54
31	The Effect of Silymarin on Oral Nifedipine Pharmacokinetics. <i>Planta Medica</i> , 2007, 73, 1429-1435.	1.3	53
32	Drug Cocktail Interaction Study on the Effect of the Orally Administered Lavender Oil Preparation Silexan on Cytochrome P450 Enzymes in Healthy Volunteers. <i>Drug Metabolism and Disposition</i> , 2013, 41, 987-993.	3.3	50
33	Arginine vasopressin (AVP) and treatment with arginine vasopressin receptor antagonists (vaptans) in congestive heart failure, liver cirrhosis and syndrome of inappropriate antidiuretic hormone secretion (SIADH). <i>European Journal of Clinical Pharmacology</i> , 2011, 67, 333-346.	1.9	42
34	A Physiologically Based Pharmacokinetic Model of Voriconazole Integrating Time-Dependent Inhibition of CYP3A4, Genetic Polymorphisms of CYP2C19 and Predictions of Drug-Drug Interactions. <i>Clinical Pharmacokinetics</i> , 2020, 59, 781-808.	3.5	42
35	How may Anticancer Chemotherapy with Fluorouracil be Individualised?. <i>Clinical Pharmacokinetics</i> , 2006, 45, 567-592.	3.5	41
36	Effect of the CYP2C8 Genotype on the Pharmacokinetics and Pharmacodynamics of Repaglinide. <i>Drug Metabolism and Disposition</i> , 2011, 39, 927-932.	3.3	41

#	ARTICLE	IF	CITATIONS
37	Predictors of Inadequate Linezolid Concentrations after Standard Dosing in Critically Ill Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 5254-5261.	3.2	39
38	Quantification of cyclophosphamide and its metabolites in urine using liquid chromatography/tandem mass spectrometry. <i>Rapid Communications in Mass Spectrometry</i> , 2004, 18, 1472-1478.	1.5	37
39	Affinities of Dihydrocodeine and its Metabolites to Opioid Receptors. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2002, 91, 57-63.	0.0	35
40	Do activities of cytochrome P450 (CYP)3A, CYP2D6 and P-glycoprotein differ between healthy volunteers and HIV-infected patients?. <i>Antiviral Therapy</i> , 2010, 15, 975-983.	1.0	35
41	Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 749-763.	2.3	35
42	Interaction of pefloxacin and enoxacin with the human cytochrome P450 enzyme CYP1A2. <i>Clinical Pharmacology and Therapeutics</i> , 1999, 65, 262-274.	4.7	34
43	Influence of posture on pharmacokinetics. <i>European Journal of Clinical Pharmacology</i> , 2009, 65, 109-119.	1.9	34
44	Impact of Impaired Renal Function on the Pharmacokinetics of the Antiepileptic Drug Lacosamide. <i>Clinical Pharmacokinetics</i> , 2013, 52, 897-906.	3.5	33
45	A Semiphysiological Population Pharmacokinetic Model for Dynamic Inhibition of Liver and Gut Wall Cytochrome P450 3A by Voriconazole. <i>Clinical Pharmacokinetics</i> , 2013, 52, 763-781.	3.5	33
46	Pharmacokinetics of remdesivir in a COVID-19 patient with end-stage renal disease on intermittent haemodialysis. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 825-827.	3.0	33
47	Pharmacokinetics, Pharmacodynamics, and Comparative Bioavailability of Single, Oral 2-mg Doses of Dexamethasone Liquid and Tablet Formulations: A Randomized, Controlled, Crossover Study in Healthy Adult Volunteers. <i>Clinical Therapeutics</i> , 2011, 33, 1831-1841.	2.5	32
48	Assessment of Pharmacokinetic Drug-Drug Interactions in Humans: In Vivo Probe Substrates for Drug Metabolism and Drug Transport Revisited. <i>Annual Review of Pharmacology and Toxicology</i> , 2019, 59, 507-536.	9.4	32
49	Inhibitory Effects of Trosipium Chloride on Cytochrome P450 Enzymes in Human Liver Microsomes. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1999, 85, 299-304.	0.0	31
50	Cytochrome P-450 Enzymes Contributing to Demethylation of Maprotiline in Man. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2002, 90, 144-149.	0.0	29
51	A Novel Toxicokinetic Modeling of Cypermethrin and Permethrin and Their Metabolites in Humans for Dose Reconstruction from Biomarker Data. <i>PLoS ONE</i> , 2014, 9, e88517.	2.5	28
52	Study on the Dosing Accuracy of Commonly Used Disposable Insulin Pens. <i>Diabetes Technology and Therapeutics</i> , 2012, 14, 804-809.	4.4	26
53	Natriuretic peptides in therapy for decompensated heart failure. <i>European Journal of Clinical Pharmacology</i> , 2012, 68, 223-230.	1.9	25
54	Optimization of linezolid therapy in the critically ill: the effect of adjusted infusion regimens. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2304-2310.	3.0	25

#	ARTICLE	IF	CITATIONS
55	Plasma and Tissue Pharmacokinetics of Epirubicin and Paclitaxel in Patients Receiving Neoadjuvant Chemotherapy for Locally Advanced Primary Breast Cancer. <i>Clinical Pharmacology and Therapeutics</i> , 2007, 81, 659-668.	4.7	24
56	Improvement in the handling of drug-drug interactions. <i>European Journal of Clinical Pharmacology</i> , 2008, 64, 167-171.	1.9	24
57	Population pharmacokinetic analysis of circadian rhythms in hepatic CYP3A activity using midazolam. <i>Journal of Clinical Pharmacology</i> , 2014, 54, 1162-1169.	2.0	23
58	Biotransformation of methylxanthines in mammalian cell lines genetically engineered for expression of single cytochrome P450 isoforms. Allocation of metabolic pathways to isoforms and inhibitory effects of quinolones. <i>Toxicology</i> , 1993, 82, 169-189.	4.2	22
59	Differences in caffeine and paraxanthine metabolism between human and murine CYP1A2. <i>Biochemical Pharmacology</i> , 2002, 63, 2159-2167.	4.4	22
60	Pharmacokinetics and pharmacodynamics of moist inhalation epinephrine using a mobile inhaler. <i>European Journal of Clinical Pharmacology</i> , 2013, 69, 1303-1310.	1.9	21
61	Modeling the Autoinhibition of Clarithromycin Metabolism during Repeated Oral Administration. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 2892-2901.	3.2	20
62	A Clinical Drug-Drug Interaction Study Assessing a Novel Drug Transporter Phenotyping Cocktail With Adefovir, Sitagliptin, Metformin, Pitavastatin, and Digoxin. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 1398-1407.	4.7	19
63	Intermittent high-dose treatment with erlotinib enhances therapeutic efficacy in EGFR-mutant lung cancer. <i>Oncotarget</i> , 2015, 6, 38458-38468.	1.8	19
64	Study of coumarin metabolism by human liver microsomes using capillary electrophoresis. <i>Analytica Chimica Acta</i> , 1995, 310, 101-107.	5.4	18
65	Population Pharmacokinetics of the BEACOPP Polychemotherapy Regimen in Hodgkin's Lymphoma and its Effect on Myelotoxicity. <i>Clinical Pharmacokinetics</i> , 2007, 46, 319-333.	3.5	18
66	Drinking Ethanol Has Few Acute Effects on CYP2C9, CYP2C19, NAT2, and P-glycoprotein Activities but Somewhat Inhibits CYP1A2, CYP2D6, and Intestinal CYP3A: So What?. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 1249-1259.	4.7	18
67	Phenotyping of N-acetyltransferase type 2 by caffeine from uncontrolled dietary exposure. <i>European Journal of Clinical Pharmacology</i> , 2004, 60, 17-21.	1.9	17
68	Identification of a novel non-functional CYP2D6 allele, CYP2D6*69, in a Caucasian poor metabolizer individual. <i>European Journal of Clinical Pharmacology</i> , 2009, 65, 97-100.	1.9	17
69	Bioequivalence between novel ready-to-use liquid formulations of the recombinant human GH Omnitrope and the original lyophilized formulations for reconstitution of Omnitrope and Genotropin. <i>European Journal of Endocrinology</i> , 2010, 162, 1051-1058.	3.7	17
70	Development and validation of an in vitro, seven-in-one human cytochrome P450 assay for evaluation of both direct and time-dependent inhibition. <i>Journal of Pharmacological and Toxicological Methods</i> , 2016, 77, 66-75.	0.7	16
71	Physiologically-based pharmacokinetic modeling of dextromethorphan to investigate interindividual variability within CYP2D6 activity score groups. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2022, 11, 494-511.	2.5	16
72	Phenotyping Studies to Assess the Effects of Phytopharmaceuticals on In Vivo Activity of Main Human Cytochrome P450 Enzymes. <i>Planta Medica</i> , 2012, 78, 1428-1457.	1.3	14

#	ARTICLE	IF	CITATIONS
73	Sorafenib and everolimus in patients with advanced solid tumors and KRAS-mutated NSCLC: A phase I trial with early pharmacodynamic FDG-PET assessment. <i>Cancer Medicine</i> , 2020, 9, 4991-5007.	2.8	14
74	Torsades de pointes tachycardia induced by common cold compound medication containing chlorpheniramine. <i>European Journal of Clinical Pharmacology</i> , 2010, 66, 1173-1175.	1.9	13
75	Phenotyping of N-acetyltransferase type 2 and xanthine oxidase with caffeine: when should urine samples be collected?. <i>European Journal of Clinical Pharmacology</i> , 2009, 65, 411-417.	1.9	12
76	Modeling NSCLC Progression: Recent Advances and Opportunities Available. <i>AAPS Journal</i> , 2013, 15, 542-550.	4.4	12
77	Modeling Tumor Dynamics and Overall Survival in Advanced Non-Small-Cell Lung Cancer Treated with Erlotinib. <i>Journal of Thoracic Oncology</i> , 2015, 10, 84-92.	1.1	12
78	Combinations of common SNPs of the transporter gene ABCB1 influence apparent bioavailability, but not renal elimination of oral digoxin. <i>Scientific Reports</i> , 2020, 10, 12457.	3.3	12
79	What is the true risk of a pharmacokinetic drug-drug interaction?. <i>European Journal of Clinical Pharmacology</i> , 2007, 63, 897-899.	1.9	11
80	Mesalazine pharmacokinetics and NAT2 phenotype. <i>European Journal of Clinical Pharmacology</i> , 2009, 65, 47-54.	1.9	11
81	Quantification of mephenytoin and its metabolites 4-hydroxymephenytoin and nirvanol in human urine using a simple sample processing method. <i>Rapid Communications in Mass Spectrometry</i> , 2004, 18, 1675-1680.	1.5	10
82	The role of human cytochrome P450 enzymes in metabolism of acrylamide <i>in vitro</i> . <i>Toxicology Mechanisms and Methods</i> , 2013, 23, 346-351.	2.7	10
83	A HILIC-MS/MS assay for the quantification of metformin and sitagliptin in human plasma and urine: A tool for studying drug transporter perturbation. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2019, 175, 112754.	2.8	10
84	Prediction of exposure-driven myelotoxicity of continuous infusion 5-fluorouracil by a semi-physiological pharmacokinetic-pharmacodynamic model in gastrointestinal cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 711-722.	2.3	10
85	Evaluation of body-surface-area adjusted dosing of high-dose methotrexate by population pharmacokinetics in a large cohort of cancer patients. <i>BMC Cancer</i> , 2021, 21, 719.	2.6	10
86	Determination of soluble vascular endothelial growth factor receptor 3 (sVEGFR-3) in plasma as pharmacodynamic biomarker. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2012, 70, 485-491.	2.8	9
87	Sorafenib in the Treatment of Early Breast Cancer: Results of the Neoadjuvant Phase II Study - SOFIA*. <i>Breast Care</i> , 2014, 9, 169-174.	1.4	9
88	Brain Exposure to Piperacillin in Acute Hemorrhagic Stroke Patients Assessed by Cerebral Microdialysis and Population Pharmacokinetics. <i>Neurocritical Care</i> , 2020, 33, 740-748.	2.4	9
89	Clinical Pharmacokinetics and Pharmacodynamics of Cefiderocol. <i>Clinical Pharmacokinetics</i> , 2021, 60, 1495-1508.	3.5	9
90	Absence of Effect of Rufloxacin on Theophylline Pharmacokinetics in Steady State. <i>Antimicrobial Agents and Chemotherapy</i> , 1998, 42, 2359-2364.	3.2	8

#	ARTICLE	IF	CITATIONS
91	Assessment of urinary mephenytoin metrics to phenotype for CYP2C19 and CYP2B6 activity. <i>European Journal of Clinical Pharmacology</i> , 2008, 64, 387-398.	1.9	8
92	The effect of organic solvents on enzyme kinetic parameters of human CYP3A4 and CYP1A2 in vitro. <i>Toxicology Mechanisms and Methods</i> , 2013, 23, 576-583.	2.7	8
93	Channeling the flood of meta-analyses. <i>European Journal of Clinical Pharmacology</i> , 2015, 71, 645-647.	1.9	8
94	Ciprofloxacin in critically ill subjects: considering hepatic function, age and sex to choose the optimal dose. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 682-690.	3.0	8
95	Rationale of a lower dexamethasone dose in prenatal congenital adrenal hyperplasia therapy based on pharmacokinetic modelling. <i>European Journal of Endocrinology</i> , 2021, 185, 365-374.	3.7	8
96	Developing a Nationwide Infrastructure for Therapeutic Drug Monitoring of Targeted Oral Anticancer Drugs: The ON-TARGET Study Protocol. <i>Cancers</i> , 2021, 13, 6281.	3.7	8
97	Clinical impact of fluvoxamine-mediated long QTU syndrome. <i>European Journal of Clinical Pharmacology</i> , 2012, 68, 109-111.	1.9	7
98	A Modeling and Simulation Framework for Adverse Events in Erlotinib-Treated Non-Small-Cell Lung Cancer Patients. <i>AAPS Journal</i> , 2015, 17, 1483-1491.	4.4	7
99	Quantification of Bisoprolol and Metoprolol in Simultaneous Human Serum and Cerebrospinal Fluid Samples. <i>Pharmacology</i> , 2018, 101, 29-34.	2.2	7
100	A Single Dose of Baicalin Has No Clinically Significant Effect on the Pharmacokinetics of Cyclosporine A in Healthy Chinese Volunteers. <i>Frontiers in Pharmacology</i> , 2019, 10, 518.	3.5	7
101	The genotype does not influence sildenafil pharmacokinetics in healthy volunteers. <i>Clinical Pharmacology and Therapeutics</i> , 2005, 78, 441-443.	4.7	6
102	Modelling ocular pharmacokinetics of fluorescein administered as lyophilisate or conventional eye drops. <i>European Journal of Clinical Pharmacology</i> , 2008, 64, 521-529.	1.9	6
103	Quantifying the Effect of Covariates on Concentrations and Effects of Steady-State Phenprocoumon Using a Population Pharmacokinetic/Pharmacodynamic Model. <i>Clinical Pharmacokinetics</i> , 2013, 52, 359-371.	3.5	5
104	Quantification of Hydrochlorothiazide and Ramipril/Ramiprilate in Blood Serum and Cerebrospinal Fluid: A Pharmacokinetic Assessment of Central Nervous System Adverse Effects. <i>Pharmacology</i> , 2018, 102, 133-137.	2.2	5
105	A population pharmacokinetic model of intravenous telavancin in healthy individuals to assess tissue exposure. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2019, 392, 1097-1106.	3.0	5
106	A Population Pharmacokinetic Model of (R)- and (S)- Oxybutynin and Its Active Metabolites After Oral and Intravesical Administration to Healthy Volunteers. <i>Journal of Clinical Pharmacology</i> , 2021, 61, 961-971.	2.0	5
107	Quantification of adefovir and pitavastatin in human plasma and urine by LC-MS/MS: A useful tool for drug-drug interaction studies. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2019, 1125, 121718.	2.3	4
108	The parent drugs chloroquine and hydroxychloroquine do not inhibit human CYP3A activity in vitro. <i>European Journal of Clinical Pharmacology</i> , 2020, 76, 1481-1482.	1.9	4

#	ARTICLE	IF	CITATIONS
109	A Novel Study Design Using Continuous Intravenous and Intraduodenal Infusions of Midazolam and Voriconazole for Mechanistic Quantitative Assessment of Hepatic and Intestinal CYP3A Inhibition. <i>Journal of Clinical Pharmacology</i> , 2020, 60, 1237-1253.	2.0	4
110	Influence of Genetic Polymorphisms of VKORC1 and CYP2C9 in Patients on Phenprocoumon Steady-State Dose Requirements. <i>Blood</i> , 2008, 112, 4051-4051.	1.4	4
111	Pharmacokinetic Phenotyping to Predict Drug-Drug Interactions: Time to Divorce the Hybrid Concept of Simultaneous Mechanistic-Based and Exposure-Based Assessment. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 42-42.	4.7	3
112	Response to the Impact of Acute Alcohol Exposure on P-glycoprotein Function at the Blood-Brain Barrier Assessed Using 11 C-Metoclopramide PET Imaging. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 814-814.	4.7	3
113	Pharmacokinetics of metronomic temozolomide in cerebrospinal fluid of children with malignant central nervous system tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, 89, 617-627.	2.3	3
114	Pharmacogenetic-Based Clinical Scores: A Useful, Simple Tool to Predict Tamoxifen-Based CYP2D6 Phenotype?. <i>Journal of Clinical Pharmacology</i> , 2010, 50, 370-372.	2.0	2
115	Adverse events during placebo vs. no drug administration—results of a randomised interventional trial in 160 volunteers. <i>European Journal of Clinical Pharmacology</i> , 2015, 71, 1403-1405.	1.9	2
116	Comparison of Pantoprazole Concentrations in Simultaneous Cerebrospinal Fluid and Serum Samples. <i>Pharmacology</i> , 2016, 98, 70-72.	2.2	2
117	Assessment of inhibitory effects on major human cytochrome P450 enzymes by spasmolytics used in the treatment of overactive bladder syndrome. <i>Therapeutic Advances in Urology</i> , 2017, 9, 163-177.	2.0	2
118	A Model-Based Approach to Assess Unstable Creatinine Clearance in Critically Ill Patients. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 1240-1249.	4.7	2
119	Theophylline metabolism affected by mexiletine. <i>Clinical Pharmacology and Therapeutics</i> , 1992, 52, 107-108.	4.7	1
120	Detection of a Novel 1905C>T Mutation within the Dihydropyrimidine Dehydrogenase Gene and Potential for Misclassification with the Exon 14-skipping Mutation. <i>Clinical Chemistry</i> , 2003, 49, 707-708.	3.2	1
121	Reporting the details of consent procedures in clinical trials. <i>Journal of Clinical Epidemiology</i> , 2020, 117, 150-151.	5.0	1
122	Erythrocyte Membrane Fluidity in Diabetics: Fluorescence Study. <i>Collection of Czechoslovak Chemical Communications</i> , 1999, 64, 548-552.	1.0	1
123	Phenotyping the activity of drug metabolizing enzymes using limited sampling strategies: Perturbations and bias. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2012, 50, 476-477.	0.6	1
124	Individual variation in factors affecting the steps between dose application and effects of antineoplastic agents. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2005, 43, 573-574.	0.6	1
125	Professor Dr. Nina Bakracheva. <i>European Journal of Clinical Pharmacology</i> , 2008, 64, 835-836.	1.9	0
126	Frequency and Types of Pathological Upper Gastrointestinal Endoscopy Findings in Clinically Healthy Individuals. <i>Drugs in R and D</i> , 2020, 20, 115-124.	2.2	0